SCHEMBL6399007

SCHEMBL6399007

O=C(Nc1ccc(C2(O)CCN(C(=O)OCc3ccccc3)CC2)cc1)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.55
POLB P06746 1/20 0.50
CHRM4 P08173 1/20 0.49
KDM1A O60341 3/20 0.49
MAOA P21397 2/20 0.49
MAOB P27338 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
NOS2 P35228 1/20 0.48
TGM2 P21980 3/20 0.48
ENPP2 Q13822 1/20 0.48
RCOR1 Q9UKL0 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
F13A1 P00488 1/20 0.48
TGM1 P22735 1/20 0.48
TP53 P04637 2/20 0.47
MAPT P10636 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7556949 0.87 CHRM4 (0.61) CCR1POLBCHRM4KDM1AMEN1
SCHEMBL16936275 0.83 CCR1 (0.64) CCR1CHRM4MEN1KMT2ANPSR1
SCHEMBL8696969 0.83 RORC (0.58) CCR1CHRM4KDM1AMEN1KMT2A
SCHEMBL19458995 0.83 ACE2 (0.56) CCR1CHRM4KDM1AMEN1KMT2A
SCHEMBL15379133 0.83 NOS2 (0.54) CCR1CHRM4KDM1AMEN1KMT2A
SCHEMBL6399505 0.83 MCHR1 (0.47) KDM1AMEN1KMT2ANPSR1NOS2
SCHEMBL751049 0.82 OPRD1 (0.53) CCR1CHRM4KDM1AMEN1KMT2A
SCHEMBL15378393 0.82 ENPP2 (0.52) CCR1CHRM4KDM1ANOS2TGM2
SCHEMBL7982809 0.82 NPC1 (0.50) CCR1KDM1AMEN1KMT2ANPSR1
SCHEMBL8315425 0.81 OPRD1 (0.54) CCR1CHRM4KDM1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050054683-A1 Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings HUTCHINSON DOUGLAS K (US) 2005-03-10 US disclosed
US-6358942-B1 MICROBIOCIDES AND BACTERICIDES FOR TREATING GRAMPOSITIVE, BACTEROIDES, CLOSTRIDIUM, MYCOBACTERIUM, STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS PHARMACIA & UPJOHN COMPANY 2002-03-19 US disclosed
US-6313307-B1 DEBLOCKING, DEPROTECTING; CATALYTIC HYDROGENATION, ALKYLATION; PREPARING MICROBIOCIDES AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, MYCOBACTERIUM, AND CLOSTRIDIUM PHARMACIA & UPJOHN COMPANY 2001-11-06 US disclosed
EP-0856002-B1 PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS UPJOHN CO (US) 2001-10-24 EP disclosed
US-6166056-A Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings PHARMACIA (US) 2000-12-26 US disclosed
US-6051716-A ANTIMICROBIAL AGENTS PHARMACIA & UPJOHN, INC. (US) 2000-04-18 US disclosed
US-6043266-A MICROBIOCIDES TREATING GRAM-POSITIVE BACTERIA INFECTIONS AND PERSONS WITH AIDS PHARMACIA & UPJOHN COMPANY (US) 2000-03-28 US disclosed
US-5968962-A ANTIMICROBIAL AGENTS; EFFECTIVE AGAINST GRAMPOSITIVE BACTERIA PHARMACIA & UPJOHN COMPANY (US) 1999-10-19 US disclosed
EP-0856002-A1 PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS PHARMACIA & UPJOHN COMPANY (US) 1998-08-05 EP disclosed
WO-1997009328-A1 PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS PHARMACIA & UPJOHN COMPANY (US) 1997-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054683-A1 Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings CBR1, NCOR1, RCOR1 CCR1 49/4885POLB 3156/4885CHRM4 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.